These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 22271092)
1. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092 [TBL] [Abstract][Full Text] [Related]
2. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. Gobbi PG; Valentino F; Bassi E; Coriani C; Merli F; Bonfante V; Marchianò A; Gallamini A; Bolis S; Stelitano C; Levis A; Federico M; Angrilli F; Di Giulio G; Corazza GR Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):396-402. PubMed ID: 21729691 [TBL] [Abstract][Full Text] [Related]
3. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Federico M Hematol Oncol; 2013 Sep; 31(3):151-5. PubMed ID: 23108910 [TBL] [Abstract][Full Text] [Related]
4. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092 [TBL] [Abstract][Full Text] [Related]
5. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946 [TBL] [Abstract][Full Text] [Related]
6. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
7. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310 [TBL] [Abstract][Full Text] [Related]
8. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ; N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708 [TBL] [Abstract][Full Text] [Related]
9. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM; Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286 [TBL] [Abstract][Full Text] [Related]
10. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207 [TBL] [Abstract][Full Text] [Related]
11. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663 [TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ; J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968 [TBL] [Abstract][Full Text] [Related]
13. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective? Hamed RH; Anter AH; Awad IA Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609 [TBL] [Abstract][Full Text] [Related]
14. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040 [TBL] [Abstract][Full Text] [Related]
15. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
16. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976 [TBL] [Abstract][Full Text] [Related]
17. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405 [TBL] [Abstract][Full Text] [Related]
19. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410 [TBL] [Abstract][Full Text] [Related]
20. [ABVD chemotherapy for Hodgkin lymphoma at a single institute]. Ohshima R; Motomura S; Hashimoto C; Miyazaki T; Ito S; Takasaki H; Hyo R; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Kanamori H; Ishigatsubo Y Rinsho Ketsueki; 2010 Dec; 51(12):1756-61. PubMed ID: 21258185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]